BACKGROUND: In jaundiced patients with suspected pancreatic cancer, endoscopic retrograde cholangiopancreatography (ERCP) with biliary stent is frequently performed prior to histologic diagnosis by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). AIMS: To compare the accuracy of jaundiced patients undergoing EUS-FNA for a pancreatic mass with or without a biliary stent. METHODS: Consecutive patients with a pancreatic mass and jaundice who underwent EUS-FNA between 4/2005 and 4/2013 were identified. Final diagnosis was based on histologic or radiologic evaluation with >6-month follow-up if the index EUS-FNA was negative for malignancy. Primary endpoint was histologic accuracy of EUS-FNA. RESULTS: Mean age of the 180 patients was 65 ± 12 years; 83 (46 %) had ERCP prior to EUS-FNA and 75 (42 %) received a biliary stent. Onsite cytopathologist was present for 81 (45 %) procedures. Final diagnosis revealed malignancy in 172 (96 %) patients, with adenocarcinoma in 159 (88 %). Patients with biliary stents had lower accuracy of EUS-FNA for malignancy than those without a biliary stent: 77 % (95 % CI 67-85 %) versus 89 % (95 % CI 81-93 %). On multivariate analysis, having a biliary stent (OR = 0.37, 95 % CI 0.15-0.90), onsite cytopathologist (OR = 9.24, 95 % CI 2.64-32.37), and receiving a core biopsy (OR = 2.60, 95 % CI 1.07-6.29) were associated with accuracy of EUS-FNA. CONCLUSIONS: Presence of a biliary stent was associated with a significant decrease in the accuracy of EUS-FNA for histologic diagnosis of pancreatic cancer, while accuracy was increased when a cytopathologist was onsite. EUS-FNA should be performed prior to ERCP in jaundiced patients with suspected pancreatic cancer.
BACKGROUND: In jaundicedpatients with suspected pancreatic cancer, endoscopic retrograde cholangiopancreatography (ERCP) with biliary stent is frequently performed prior to histologic diagnosis by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). AIMS: To compare the accuracy of jaundicedpatients undergoing EUS-FNA for a pancreatic mass with or without a biliary stent. METHODS: Consecutive patients with a pancreatic mass and jaundice who underwent EUS-FNA between 4/2005 and 4/2013 were identified. Final diagnosis was based on histologic or radiologic evaluation with >6-month follow-up if the index EUS-FNA was negative for malignancy. Primary endpoint was histologic accuracy of EUS-FNA. RESULTS: Mean age of the 180 patients was 65 ± 12 years; 83 (46 %) had ERCP prior to EUS-FNA and 75 (42 %) received a biliary stent. Onsite cytopathologist was present for 81 (45 %) procedures. Final diagnosis revealed malignancy in 172 (96 %) patients, with adenocarcinoma in 159 (88 %). Patients with biliary stents had lower accuracy of EUS-FNA for malignancy than those without a biliary stent: 77 % (95 % CI 67-85 %) versus 89 % (95 % CI 81-93 %). On multivariate analysis, having a biliary stent (OR = 0.37, 95 % CI 0.15-0.90), onsite cytopathologist (OR = 9.24, 95 % CI 2.64-32.37), and receiving a core biopsy (OR = 2.60, 95 % CI 1.07-6.29) were associated with accuracy of EUS-FNA. CONCLUSIONS: Presence of a biliary stent was associated with a significant decrease in the accuracy of EUS-FNA for histologic diagnosis of pancreatic cancer, while accuracy was increased when a cytopathologist was onsite. EUS-FNA should be performed prior to ERCP in jaundicedpatients with suspected pancreatic cancer.
Authors: Miquel Porta; Xavier Fabregat; Núria Malats; Luisa Guarner; Alfredo Carrato; Ana de Miguel; Laura Ruiz; Manuel Jariod; Sergi Costafreda; Susana Coll; Juan Alguacil; Josep M Corominas; Ricard Solà; Antonio Salas; Francisco X Real Journal: Clin Transl Oncol Date: 2005-06 Impact factor: 3.405
Authors: Marc F Catalano; Anand Sahai; Michael Levy; Joseph Romagnuolo; Maurits Wiersema; William Brugge; Martin Freeman; Kenji Yamao; Marcia Canto; Lyndon V Hernandez Journal: Gastrointest Endosc Date: 2009-02-24 Impact factor: 9.427
Authors: Julio Iglesias-Garcia; J Enrique Dominguez-Munoz; Ihab Abdulkader; Jose Larino-Noia; Elena Eugenyeva; Antonio Lozano-Leon; Jeronimo Forteza-Vila Journal: Am J Gastroenterol Date: 2011-04-12 Impact factor: 10.864
Authors: M E Cannon; S L Carpenter; G H Elta; T T Nostrant; M L Kochman; G G Ginsberg; B Stotland; E F Rosato; J B Morris; F Eckhauser; J M Scheiman Journal: Gastrointest Endosc Date: 1999-07 Impact factor: 9.427
Authors: Ali A Siddiqui; Michael Fein; Thomas E Kowalski; David E Loren; Mohamad A Eloubeidi Journal: Dig Dis Sci Date: 2012-04-21 Impact factor: 3.199
Authors: Niels A van der Gaag; Erik A J Rauws; Casper H J van Eijck; Marco J Bruno; Erwin van der Harst; Frank J G M Kubben; Josephus J G M Gerritsen; Jan Willem Greve; Michael F Gerhards; Ignace H J T de Hingh; Jean H Klinkenbijl; Chung Y Nio; Steve M M de Castro; Olivier R C Busch; Thomas M van Gulik; Patrick M M Bossuyt; Dirk J Gouma Journal: N Engl J Med Date: 2010-01-14 Impact factor: 91.245
Authors: Thomas J Savides; Michael Donohue; Gordon Hunt; Mohammed Al-Haddad; Harry Aslanian; Tamir Ben-Menachem; Victor K Chen; Walter Coyle; John Deutsch; John DeWitt; Manish Dhawan; Alexander Eckardt; Mohamad Eloubeidi; Alec Esker; Stuart R Gordon; Frank Gress; Steven Ikenberry; Ann Marie Joyce; Jason Klapman; Simon Lo; Fauze Maluf-Filho; Nicholas Nickl; Virmeet Singh; Jason Wills; Cynthia Behling Journal: Gastrointest Endosc Date: 2007-08 Impact factor: 9.427
Authors: Christoph F Dietrich; Noor L Bekkali; Sean Burmeister; Yi Dong; Simon M Everett; Michael Hocke; Andre Ignee; Wei On; Srisha Hebbar; Kofi Oppong; Siyu Sun; Christian Jenssen; Barbara Braden Journal: Endosc Ultrasound Date: 2022 May-Jun Impact factor: 5.275